A Phase 3 interventional study of placebo and Denosumab in Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one has the largest enrollment, is one of 2 that started in 2004, is one of 17 in phase 3, and was the 1st registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:
Lambda Therapeutic Research Ltd. · Sites in India
Ages 55–90 · Women only
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 60 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7,808 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 278 across the 31 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 31 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
24 studies in Osteoporosis, Postmenopausal by Amgen: none open now, none under way, none of them phase 3. Of 24 finished, 23 (96%) have results posted.
Among the 24 studies in Osteoporosis, Postmenopausal by Amgen, this one has the largest enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2004, is one of 14 in phase 3, and was the 1st registered.
Amgen’s Osteoporosis, Postmenopausal studies by the year they started, since 2004.
1 of the studies testing denosumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05010590Massachusetts General HospitalAnabolic Therapy in Postmenopausal Osteoporosis | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 24 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
This study's enrollment of 7,808 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Browse Osteoporosis, Postmenopausal studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Osteoporosis, Postmenopausal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoporosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Placebo administered subcutaneously once every 6 months for 3 years.
Drug: placebo
Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.
Drug: Denosumab
Placebo administered by subcutaneous injection
Denosumab 60 mg administered by subcutaneous injection
Also known as: AMG 162, Prolia®
Number of Participants With New Vertebral Fractures
A new vertebral fracture, assessed by lateral spine X-ray using Genant semiquantitative scoring method, was identified as an ≥ 1 grade increase from the Baseline grade of 0 in any vertebra from T4 to L4. New vertebral fractures included morphometric vertebral fractures (assessed at scheduled visits and not associated with signs or symptoms \[or both\] indicative of a fracture) and clinical vertebral fractures (assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms indicative of a fracture, excluding any fracture associated with high trauma severity or a pathologic fracture).
Time frame: 36 months
Number of Participants With Nonvertebral Fractures
Nonvertebral fractures (osteoporotic) were those occurring on study excluding those of the vertebrae (cervical, thoracic, and lumbar), skull, facial, mandible, metacarpus, finger phalanges, and toe phalanges. Fractures associated with high trauma severity (fractures that were the result of a fall from higher than the height of a stool, chair, first rung on a ladder or equivalent (\> 20 inches) or was the result of severe trauma other than a fall) and pathologic fractures were excluded from this category. Nonvertebral fractures were required to be confirmed either by radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging (MRI), or by documentation in a radiology report, surgical report, or discharge summary.
Time frame: 36 months
Number of Participants With a Hip Fracture
Hip fractures are a subset of nonvertebral fractures including femur neck, femur intertrochanter, and femur subtrochanter.
Time frame: 36 months
First Subject Enrolled: 03-Aug-2004 Last Subject Enrolled: 01-Jun-2005
| Milestone | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Started | 3906 | 3902 |
| Received study medication | 3883 | 3879 |
| Safety analysis set | 3876 | 3886 |
| Completed | 3206 | 3272 |
| Not completed | 700 | 630 |
| Withdrew: Physician decision | 6 | 3 |
| Withdrew: Adverse event | 81 | 93 |
| Withdrew: Withdrawal by subject | 403 | 344 |
| Withdrew: Death | 78 | 62 |
| Withdrew: Disease progression | 7 | 3 |
| Withdrew: Ineligibility determined | 12 | 9 |
| Withdrew: Lost to follow-up | 57 | 57 |
| Withdrew: Noncompliance | 17 | 13 |
| Withdrew: Other | 20 | 32 |
| Withdrew: Protocol deviation | 12 | 10 |
| Withdrew: Requirement for alternative therapy | 7 | 4 |
A new vertebral fracture, assessed by lateral spine X-ray using Genant semiquantitative scoring method, was identified as an ≥ 1 grade increase from the Baseline grade of 0 in any vertebra from T4 to L4. New vertebral fractures included morphometric vertebral fractures (assessed at scheduled visits and not associated with signs or symptoms \[or both\] indicative of a fracture) and clinical vertebral fractures (assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms indicative of a fracture, excluding any fracture associated with high trauma severity or a pathologic fracture).
| Participants | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Number of Participants With New Vertebral Fractures | 264 | 86 |
Nonvertebral fractures (osteoporotic) were those occurring on study excluding those of the vertebrae (cervical, thoracic, and lumbar), skull, facial, mandible, metacarpus, finger phalanges, and toe phalanges. Fractures associated with high trauma severity (fractures that were the result of a fall from higher than the height of a stool, chair, first rung on a ladder or equivalent (\> 20 inches) or was the result of severe trauma other than a fall) and pathologic fractures were excluded from this category. Nonvertebral fractures were required to be confirmed either by radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging (MRI), or by documentation in a radiology report, surgical report, or discharge summary.
| Participants | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Number of Participants With Nonvertebral Fractures | 293 | 238 |
Hip fractures are a subset of nonvertebral fractures including femur neck, femur intertrochanter, and femur subtrochanter.
| Participants | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Number of Participants With a Hip Fracture | 43 | 26 |
Collected over 36 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 972/3,876 (25.1%) | 3,107/3,876 (80.2%) |
| Denosumab 60 mg Q6M | — | 1,004/3,886 (25.8%) | 3,073/3,886 (79.1%) |
| Event | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 79/3876 | 63/3886 |
| PneumoniaInfections and infestations | 36/3876 | 34/3886 |
| Atrial fibrillationCardiac disorders | 33/3876 | 36/3886 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 25/3876 | 34/3886 |
| Angina pectorisCardiac disorders | 18/3876 | 33/3886 |
| Cerebrovascular accidentNervous system disorders | 23/3876 | 32/3886 |
| CataractEye disorders | 28/3876 | 21/3886 |
| Femur fractureInjury, poisoning and procedural complications | 28/3876 | 14/3886 |
| Myocardial infarctionCardiac disorders | 23/3876 | 25/3886 |
| Radius fractureInjury, poisoning and procedural complications | 23/3876 | 25/3886 |
| Event | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 1329/3876 | 1340/3886 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 778/3876 | 778/3886 |
| HypertensionVascular disorders | 619/3876 | 603/3886 |
| NasopharyngitisInfections and infestations | 600/3876 | 563/3886 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 430/3876 | 450/3886 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 397/3876 | 383/3886 |
| ConstipationGastrointestinal disorders | 356/3876 | 351/3886 |
| InfluenzaInfections and infestations | 334/3876 | 331/3886 |
| BronchitisInfections and infestations | 298/3876 | 297/3886 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 289/3876 | 295/3886 |
| Age, Continuous(Years) | Placebo | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| Mean | 72.3 ± 5.2 | 72.3 ± 5.2 | 72.3 ± 5.2 |
| Sex: Female, Male(Participants) | Placebo | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| Female | 3906 | 3902 | 7808 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| White or Caucasian | 3629 | 3609 | 7238 |
| Black or African American | 27 | 30 | 57 |
| Hispanic or Latino | 232 | 241 | 473 |
| Asian | 8 | 9 | 17 |
| Japanese | 4 | 7 | 11 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Other | 4 | 6 | 10 |
No study locations are listed for this record.
Ran from Aug 2004 to primary completion in Jun 2008, 46 months.
Results were first posted in Jan 2014, 5 years 6 months after primary completion. A results delay was requested in Nov 2009.
Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 46 months is above that.
Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab
Osteoporosis, Postmenopausal →